An Israel-based molecular diagnostics developer focused on microRNA-based tests designed to classify cancers and guide treatment decisions. The company has worked on laboratory-developed diagnostic assays for tumors of unknown origin and other oncology indications, positioning it within the niche of...
No congressional trades have been disclosed for Rosetta Genomics Ltd. - ordinary (ROSG) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.